Diagnostic challenges of clinically significant portal hypertension in geriatric metabolic dysfunction-associated fatty liver disease: A case report
Authors:
- Femmy Nurul AkbarFAFemmy Nurul Akbar
- Nikko DarnindroNDNikko Darnindro
- Annisa Ayu WardhaniAWAnnisa Ayu Wardhani
- Safira Rosiana ChoiridaSCSafira Rosiana Choirida
- Shafa Nada SaphiraSSShafa Nada Saphira
- Griffith IsmedGIGriffith Ismed
- Ida Ayu Made KshantiIKIda Ayu Made Kshanti
- Syifa MustikaSMSyifa Mustika
- Hari HendartoHHHari Hendarto
Open Access
- 27 February 2026
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 18 (2)
Abstract
BACKGROUND Metabolic dysfunction-associated fatty liver disease (MAFLD) may progress to cirrhosis and lead to serious complications. Lipid accumulation, hepatocellular ballooning, and sinusoidal endothelial dysfunction increase intrahepatic vascular resistance, resulting in early clinically significant portal hypertension (CSPH). Although hepatic venous pressure gradient (HVPG) remains the gold standard, decompensated cirrhosis may yield deceptively low values. Transient elastography and platelet count provide supportive diagnostic evidence, yet obesity can overestimate disease severity. This report highlights the diagnostic challenge of CSPH, especially MAFLD in geriatric patients. CASE SUMMARY A 78-year-old woman with class I obesity, type 2 diabetes mellitus, and dyslipidemia presented with hematemesis and melena for a three-day period. A prior computed tomography scan revealed moderate diffuse hepatic steatosis, splenic vein dilatation, and splenomegaly. On admission, she presented with pallor, epigastric tenderness, splenomegaly, and mild ascites. Laboratory findings showed anemia, thrombocytopenia, hypoalbuminemia, and hyperglycemia. Abdominal ultrasound confirmed chronic liver disease with splenomegaly. Esophagogastroduodenoscopy demonstrated grade II-III esophageal varices and portal hypertensive gastropathy. Noninvasive fibrosis assessments (non-alcoholic fatty liver disease fibrosis score, aspartate transaminase-to-platelet ratio index, fibrosis-4 index, and FibroScan: E = 28 kPa, controlled attenuation parameter = 191 dB/m) indicated advanced hepatic fibrosis. HVPG measurement was not performed, however due to the Baveno VII criteria (transient elastography ≥ 25 kPa and platelet count < 150 × 109/L), confirmed the diagnosis of CSPH. The patient received endoscopic variceal ligation, a nonselective beta-blocker, a proton pump inhibitor, insulin, a sodium-glucose cotransporter 2 inhibitor, and lifestyle modification, resulting in clinical improvement. CONCLUSION Early and precise evaluation of CSPH in geriatric MAFLD requires an integrated clinical assessment to optimize diagnosis, management, and improve outcomes.Keywords
This publication has 21 references indexed in Scilit:
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseHepatology International, 2025
- Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunitiesEuropean Journal of Medicinal Chemistry, 2024
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLDJournal of Hepatology, 2024
- Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case reportJHEP Reports, 2022
- Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectivesPortal Hypertension & Cirrhosis, 2022
- Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosisJournal of Hepatology, 2021
- Accuracy of non-invasive methods/models for predicting esophageal varices in patients with compensated advanced chronic liver disease secondary to nonalcoholic fatty liver diseaseAnnals of Hepatology, 2021
- MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter studyLiver International, 2020
- Beta-blockers in cirrhosis: Evidence-based indications and limitationsJHEP Reports, 2020